BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Genmab A/S and neurology and rare diseases company Shire plc . The other two were British Biotech plc...
...BCIQ: BioCentury Online Intelligence Company Total raised Peak valuation (date) Barriers to growth/ independence Outcome British Biotech plc...
BioCentury | Apr 28, 2017
Finance

A different animal?

...specialist investors that should Circassia’s clinical programs fail, the effects could be as bad as British Biotech plc’s...
BioCentury | Jul 21, 2016
Strategy

Brexit of brains

...In the mid-1990s, the start-up scene took a hit from the high profile failure of British Biotech plc...
BioCentury | Jun 27, 2016
Finance

Nine lives?

...the country's life sciences industry. U.K. biotech's first brush with death came in 1998, when British Biotech plc...
BioCentury | May 19, 2016
Strategy

Mind the gap

...and early 2000s when several of the highly promising firms failed." Notable among them was British Biotech plc...
BioCentury | Mar 17, 2014
Finance

Circassia raises expectations

...ceradenovec gene therapy never made it past regulators. Investors already had bad memories of the British Biotech plc...
BioCentury | Apr 15, 2013
Company News

Oxford GlycoSciences Ltd. board of directors update

...Abingdon, U.K. Business: Drug discovery Appointed: James Noble, as a non-executive director; formerly finance director, British Biotech plc...
BioCentury | Nov 10, 2011
Targets & Mechanisms

Countering chemo-induced metastasis

...the late 1990s and early 2000s, several companies-including Bayer AG , Bristol-Myers Squibb Co. , British Biotech plc...
BioCentury | Jun 23, 2011
Targets & Mechanisms

A bid to revive MMP inhibitors

...safety profile. Academics contacted by SciBX think previous failures of MMP inhibitors-most notably marimastat from British Biotech plc...
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

...$4M ($1M per license) Up to $152M (up to $38M per license; 4 licenses) 2000 British Biotech plc...
Items per page:
1 - 10 of 245
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Genmab A/S and neurology and rare diseases company Shire plc . The other two were British Biotech plc...
...BCIQ: BioCentury Online Intelligence Company Total raised Peak valuation (date) Barriers to growth/ independence Outcome British Biotech plc...
BioCentury | Apr 28, 2017
Finance

A different animal?

...specialist investors that should Circassia’s clinical programs fail, the effects could be as bad as British Biotech plc’s...
BioCentury | Jul 21, 2016
Strategy

Brexit of brains

...In the mid-1990s, the start-up scene took a hit from the high profile failure of British Biotech plc...
BioCentury | Jun 27, 2016
Finance

Nine lives?

...the country's life sciences industry. U.K. biotech's first brush with death came in 1998, when British Biotech plc...
BioCentury | May 19, 2016
Strategy

Mind the gap

...and early 2000s when several of the highly promising firms failed." Notable among them was British Biotech plc...
BioCentury | Mar 17, 2014
Finance

Circassia raises expectations

...ceradenovec gene therapy never made it past regulators. Investors already had bad memories of the British Biotech plc...
BioCentury | Apr 15, 2013
Company News

Oxford GlycoSciences Ltd. board of directors update

...Abingdon, U.K. Business: Drug discovery Appointed: James Noble, as a non-executive director; formerly finance director, British Biotech plc...
BioCentury | Nov 10, 2011
Targets & Mechanisms

Countering chemo-induced metastasis

...the late 1990s and early 2000s, several companies-including Bayer AG , Bristol-Myers Squibb Co. , British Biotech plc...
BioCentury | Jun 23, 2011
Targets & Mechanisms

A bid to revive MMP inhibitors

...safety profile. Academics contacted by SciBX think previous failures of MMP inhibitors-most notably marimastat from British Biotech plc...
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

...$4M ($1M per license) Up to $152M (up to $38M per license; 4 licenses) 2000 British Biotech plc...
Items per page:
1 - 10 of 245